Cancer Today. (n.d.). Retrieved September 11 (2024) from https://gco.iarc.who.int/today/en

Cohen EEW, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Vokes EE (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncology: Official J Am Soc Clin Oncol 32(25):2735–2743. https://doi.org/10.1200/JCO.2013.54.6309

Article  CAS  Google Scholar 

Drawing Survival Curves using ggplot2 [R package survminer version 0.4.9]. (2021) https://doi.org/10.32614/CRAN.PACKAGE.SURVMINER

Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky M-C, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Bourhis J (2018) Induction chemotherapy followed by Cetuximab Radiotherapy is not Superior to Concurrent Chemoradiotherapy for Head and Neck carcinomas: results of the GORTEC 2007-02 phase III Randomized Trial. J Clin Oncology: Official J Am Soc Clin Oncol 36(31):3077–3083. https://doi.org/10.1200/JCO.2017.76.2591

Article  CAS  Google Scholar 

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Annals Oncology: Official J Eur Soc Med Oncol 28(9):2206–2212. https://doi.org/10.1093/annonc/mdx299. Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group

Article  CAS  Google Scholar 

Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M (2013a) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264. https://doi.org/10.1016/S1470-2045(13)70011-1

Article  CAS  PubMed  Google Scholar 

Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M (2013b) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264. https://doi.org/10.1016/S1470-2045(13)70011-1

Article  CAS  PubMed  Google Scholar 

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ, Spanish Head and Neck Cancer Cooperative Group (TTCC) (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Annals Oncology: Official J Eur Soc Med Oncol 25(1):216–225. https://doi.org/10.1093/annonc/mdt461

Article  CAS  Google Scholar 

Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation. J Natl Cancer Inst. 2015 Dec 16;108(4):djv368. https://doi.org/10.1093/jnci/djv368

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Reviews Disease Primers 6(1). https://doi.org/10.1038/S41572-020-00224-3

Kiong KL, de Souza NN, Sultana R, Iyer NG (2018) Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck. Laryngoscope 128(7):1594–1601. https://doi.org/10.1002/lary.27011

Article  PubMed  Google Scholar 

Lee Y-G, Kang EJ, Keam B, Choi J-H, Kim J-S, Park KU, Lee KE, Kim HJ, Lee K-W, Kim MK, Ahn HK, Shin SH, Kim HR, Kim S-B, Yun HJ (2022) Induction chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck squamous cell carcinoma: the Concept of Chemo-Selection (KCSG HN13-01). Cancer Res Treat 54(1):109–117. https://doi.org/10.4143/crt.2020.1329

Article  PubMed  Google Scholar 

Liu Y-P, Zheng C-C, Huang Y-N, He M-L, Xu WW, Li B (2021) Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm 2(3):315–340. https://doi.org/10.1002/mco2.55

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Wang LS, Mehra R, Flieder DB, Ridge JA (2016) Survival impact of increasing time to treatment initiation for patients with Head and Neck Cancer in the United States. J Clin Oncology: Official J Am Soc Clin Oncol 34(2):169–178. https://doi.org/10.1200/JCO.2015.61.5906

Article  CAS  Google Scholar 

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio R del, Venkatesan C, Romanov V, Haddad I (2007) R. I. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. The New England Journal of Medicine, 357(17), 1705–1715. https://doi.org/10.1056/NEJMOA070956

Therneau TM (2024) Survival Analysis [R package survival version 3.7-0]. https://doi.org/10.32614/CRAN.PACKAGE.SURVIVAL

Zhang Q, Xu T, Shen C, Qian W, Ying H, He X, Wang Y, Ji Q, Hu C, Zhou X, Lu X (2023) Response to induction chemotherapy predicts survival outcomes in oropharyngeal cancer. Cancer Med 12(8):9175–9185. https://doi.org/10.1002/cam4.5656

Article  PubMed  PubMed Central  Google Scholar 

Zhao X, Zhou Y, Peng G, Wen L, Hong X, Hu Y, Wu B, Liu X, Zhang Z, Xiao G, JingHuang, Ding Q, Yang C, Xiong X, Ma H, Shi L, Yang J, Wei J, Qin Y, Yang K (2024) Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma. Oral Oncol 156:106918. https://doi.org/10.1016/j.oraloncology.2024.106918

Article  CAS  PubMed  Google Scholar